Vutrisiran and Tafamidis in Transthyretin Amyloidosis Cardiomyopathy: Evaluating Combination Therapy Insights from HELIOS-B
Highlight
– Vutrisiran, an RNA interference agent, significantly improves clinical outcomes in transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
– Treatment effects of vutrisiran on survival and cardiovascular events were consistent irrespective of prior tafamidis use.
– Patients on background tafamidis showed numerically smaller effect sizes but no significant interaction in outcomes.
– These findings support the rationale and need for prospective trials evaluating combination therapy with transthyretin stabilizers and RNA interference therapeutics.
Study Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.